TABLE 3.
Pharmacokinetic parameters of DX-2930 in cynomolgus monkeys
| Group | Route | Cmax | AUClast | CL | Vss | t½ |
|---|---|---|---|---|---|---|
| μg/ml | h × μg/ml | ml/h/kg | ml/kg | h | ||
| 1 | i.v. | 519.7 (133.1) | 116,447.4a (16463.2) | 0.14 (0.03) | 86.3 (5.6) | 463.8 (68.9) |
| 2 | s.c. | 162.8 (26.3) | 77,024.8a (6252.0) | 0.23 (0.02) | NA | 301.1 (5.4) |
a The percent bioavailability when administered by the s.c. route was approximately 66% (s.c. AUClast/i.v. AUClast), where AUClast is area under the curve from time 0 to the time of last quantifiable concentration; Vss is apparent volume of distribution at steady state; CL is clearance. Values in parentheses are standard errors of the mean as determined by WinNonlin noncompartmental analyses (Pharsight).